Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, Fujian, China.
The Fourth Department of Intensive Care Unit, Fuzhou University Affiliated Provincial Hospital, Fuzhou, 350001, Fujian, China.
BMC Cardiovasc Disord. 2024 Aug 24;24(1):448. doi: 10.1186/s12872-024-04101-9.
This study aimed to identify the incidence, risk factors, and outcomes of permanent pacemaker (PPM) implantation after transcatheter aortic valve implantation (TAVI) procedures.
A retrospective analysis was conducted on 70 patients who underwent TAVI at the Department of Cardiology, Fujian Provincial Hospital, from January 2018 to March 2022. Based on whether a new PPM was implanted after TAVI, all patients were divided into two groups: NEW PPM and NO PPM. Baseline characteristics and clinical data were compared between the two groups. Univariate analysis was used to analyze different variables between the two groups. A binary logistic regression analysis was used to evaluate independent correlates for PPM implantation after TAVI.
The mean age of the 70 patients was 73.1 ± 8.8 years. The incidence of PPM implantation was 17.1%. Patients with diabetes and chronic kidney disease were more likely to require PPM (50% vs. 20.7%, p = 0.042, 25% vs. 5.2%, p = 0.042). Our study did not identify any significant differences in the incidence of electrocardiographic conduction disturbances except for the previous right bundle branch block (RBBB) (NO PPM 6.9% vs. NEW PPM 33.3%, p < 0.05). We found that prosthesis size, implantation depth, procedural duration, and length of hospital and intensive care unit (ICU) stays were comparable between the two groups. The leading independent predictors of PPM implantation were previous RBBB (odds ratio 10.129, p = 0.034).
The previous RBBB was the leading independent predictor of PPM implantation. New PPM was not associated with significantly new-onset left BBB, extended post-procedure hospitalization, ICU stay, or procedural duration.
本研究旨在确定经导管主动脉瓣置换术(TAVI)后永久性心脏起搏器(PPM)植入的发生率、危险因素和结局。
对 2018 年 1 月至 2022 年 3 月在福建省立医院心内科接受 TAVI 的 70 例患者进行回顾性分析。根据 TAVI 后是否植入新的 PPM,所有患者分为两组:NEW PPM 和 NO PPM。比较两组患者的基线特征和临床资料。采用单因素分析比较两组间不同变量的差异。采用二项逻辑回归分析评估 TAVI 后 PPM 植入的独立相关因素。
70 例患者的平均年龄为 73.1±8.8 岁。PPM 植入的发生率为 17.1%。患有糖尿病和慢性肾脏病的患者更有可能需要 PPM(50% vs. 20.7%,p=0.042;25% vs. 5.2%,p=0.042)。除先前存在的右束支传导阻滞(RBBB)(NO PPM 为 6.9%,NEW PPM 为 33.3%,p<0.05)外,我们的研究未发现心电图传导障碍的发生率有任何显著差异。我们发现两组之间的瓣膜尺寸、植入深度、手术时间以及住院和重症监护病房(ICU)的住院时间无显著差异。PPM 植入的主要独立预测因素是先前存在的 RBBB(优势比 10.129,p=0.034)。
先前存在的 RBBB 是 PPM 植入的主要独立预测因素。新的 PPM 与新发生的左束支完全阻滞、延长术后住院时间、ICU 入住时间或手术时间无关。